Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.

Literature DB >> 18460636

Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.

Daniel Curcio.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2008 PMID： 18460636 PMCID： PMC2395114 DOI： 10.1128/JCM.02494-07

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

× No keyword cloud information.

4 in total

1. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors: Wolfgang A Krueger; Volkhard A J Kempf; Manou Peiffer; Udo Nagele; Klaus E Unertl; Torsten H Schroeder
Journal: J Clin Microbiol Date: 2007-12-12 Impact factor: 5.948

Review 2. Tigecycline.

Authors: George A Pankey
Journal: J Antimicrob Chemother Date: 2005-07-22 Impact factor: 5.790

Review 3. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.

Authors: J Rello
Journal: J Chemother Date: 2005-08 Impact factor: 1.714

4. Rapid development of Acinetobacter baumannii resistance to tigecycline.

Authors: Gail E Reid; Shellee A Grim; Christine A Aldeza; William M Janda; Nina M Clark
Journal: Pharmacotherapy Date: 2007-08 Impact factor: 4.705

4 in total

11 in total

1. Ertapenem-induced reduction in valproate levels: case report and review of the literature.

Authors: Duane Bates; Michael Parkins; Keltie Duggan
Journal: Can J Hosp Pharm Date: 2010-07

2. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Authors: Teresa Spanu; Giulia De Angelis; Michela Cipriani; Barbara Pedruzzi; Tiziana D'Inzeo; Maria Adriana Cataldo; Gabriele Sganga; Evelina Tacconelli
Journal: Antimicrob Agents Chemother Date: 2012-05-29 Impact factor: 5.191

3. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.

Authors: Burke A Cunha
Journal: J Clin Microbiol Date: 2009-05 Impact factor: 5.948

4. Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli.

Authors: Jennifer M Adams-Haduch; Brian A Potoski; Hanna E Sidjabat; David L Paterson; Yohei Doi
Journal: Antimicrob Agents Chemother Date: 2009-03-30 Impact factor: 5.191

5. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.

Authors: Martti Vaara; Osmo Siikanen; Juha Apajalahti; John Fox; Niels Frimodt-Møller; Hui He; Anima Poudyal; Jian Li; Roger L Nation; Timo Vaara
Journal: Antimicrob Agents Chemother Date: 2010-05-17 Impact factor: 5.191

6. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.

Authors: Michael J Satlin; Christine J Kubin; Jill S Blumenthal; Andrew B Cohen; E Yoko Furuya; Stephen J Wilson; Stephen G Jenkins; David P Calfee
Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191